VRPX has 36-month beta value of 0.96. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VRPX is 18.04M, and currently, short sellers hold a 3.50% ratio of that float. The average trading volume of VRPX on February 26, 2025 was 3.78M shares.
VRPX) stock’s latest price update
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has experienced a decline in its stock price by -4.24 compared to its previous closing price of 0.25. However, the company has seen a fall of -15.39% in its stock price over the last five trading days. benzinga.com reported 2025-02-14 that On Friday, Virpax Pharmaceuticals, Inc. VRPX completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).
VRPX’s Market Performance
VRPX’s stock has fallen by -15.39% in the past week, with a monthly drop of -15.58% and a quarterly drop of -60.20%. The volatility ratio for the week is 10.87% while the volatility levels for the last 30 days are 13.78% for Virpax Pharmaceuticals Inc The simple moving average for the past 20 days is -17.38% for VRPX’s stock, with a -66.56% simple moving average for the past 200 days.
VRPX Trading at -26.69% from the 50-Day Moving Average
After a stumble in the market that brought VRPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.72% of loss for the given period.
Volatility was left at 13.78%, however, over the last 30 days, the volatility rate increased by 10.87%, as shares sank -20.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.81% lower at present.
During the last 5 trading sessions, VRPX fell by -15.97%, which changed the moving average for the period of 200-days by -90.12% in comparison to the 20-day moving average, which settled at $0.2840. In addition, Virpax Pharmaceuticals Inc saw -38.22% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for VRPX
The total capital return value is set at 6.52. Equity return is now at value -594.46, with -198.45 for asset returns.
Currently, EBITDA for the company is -15.19 million with net debt to EBITDA at 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.08.
Conclusion
To put it simply, Virpax Pharmaceuticals Inc (VRPX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
